EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation

Gabriela Sanchez-Petitto, Olga Goloubeva, James Childress, Tahreem Iqbal, Jack Masur, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Vu H Duong und 5 weitere

Acta Haematologica · 2024

DOI: 10.1159/000541131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Gabriela Sanchez-Petitto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Background: Reduced-intensity conditioning (RIC) and nonmyeloablative (NMA) regimens have enabled patients with cardiovascular disease (CVD) to undergo allogeneic stem cell transplantation (allo-HSCT). However, little is known about long-term outcomes, including cardiovascular (CV) complications.

Methods

We retrospectively studied 99 consecutive patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who underwent allo-HSCT between September 1, 2013, and November 30, 2020. Overall survival (OS), progression-free survival (PFS), nonrelapse mortality (NRM), cumulative incidence of relapse, and cumulative incidence of acute and chronic graft-versus-host disease (GvHD) were compared in patients with and without CV risk factors or disease.

Results

Preexisting CVD was present in 34 of 99 patients (34%). CVD patients more commonly had reduced-intensity conditioning (91% vs. 60%, p = 0.001) and unrelated donors (56% vs. 35%, p = 0.04). Early adverse cardiac events occurred more frequently in the CVD versus no-CVD group (38% vs. 14%), particularly arrhythmias (21% vs. 5%; p = 0.04). CVD patients tended to have poorer OS and PFS outcomes (HR = 1.98, [1.00, 3.92]; HR = 1.89, [0.96–3.72], respectively). OS rate at 1, 2, and 3 years for CVD versus no-CVD patients was 66% versus 72%, 55% versus 64%, and 46% versus 62%, respectively. Causes of death in the CVD and no-CVD groups were infections (53% vs. 28%), relapsed disease (32% vs. 52%), and CV events (10% vs. 3%).

Conclusion

Based on these data, predictive models to identify patients with CVD with higher risk of post-allo-HSCT complications and mortality and strategies to mitigate these risks should be developed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansMaleFemaleMiddle AgedRetrospective StudiesAdultTransplantation ConditioningAgedTransplantation, HomologousGraft vs Host DiseaseTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

CardiotoxicityCardiovascular risk factorsMyeloid malignancies

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sanchez-Petitto, G., Goloubeva, O., Childress, J., Iqbal, T., Masur, J., An, M., Muhammad, S., Lawson, J., Li, G., Barr, B., Emadi, A., Duong, V. H., Hardy, N. M., Rapoport, A. P., Baer, M. R., Niyongere, S., & Yared, J. A. (2024). Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation. Acta Haematologica. https://doi.org/10.1159/000541131

Vancouver

Sanchez-Petitto G, Goloubeva O, Childress J, Iqbal T, Masur J, An M, et al. Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation. Acta Haematologica. 2024. doi:10.1159/000541131

BibTeX
@article{SanchezPetitto2024,
  author = {Sanchez-Petitto, Gabriela and Goloubeva, Olga and Childress, James and Iqbal, Tahreem and Masur, Jack and An, Max and Muhammad, Safwan and Lawson, Justin and Li, Grace and Barr, Brian and Emadi, Ashkan and Duong, Vu H and Hardy, Nancy M and Rapoport, Aaron P and Baer, Maria R and Niyongere, Sandrine and Yared, Jean A},
  title = {Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000541131}
}
Kostenlos starten →